Adial Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Adial Pharmaceuticals has a total shareholder equity of $4.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.9M and $671.9K respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
Faiz karşılama oranı | n/a |
Nakit | US$3.29m |
Eşitlik | US$4.28m |
Toplam yükümlülükler | US$671.88k |
Toplam varlıklar | US$4.95m |
Son finansal sağlık güncellemeleri
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ADIL's short term assets ($3.8M) exceed its short term liabilities ($671.9K).
Uzun Vadeli Yükümlülükler: ADIL has no long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ADIL is debt free.
Borcun Azaltılması: ADIL had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: ADIL has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: ADIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15% each year